お問い合わせフォーム
に入力の上、ご送信ください。詳細は折り返しメールでお伺いしますので簡単で結構です。
構造式をクリックして表示される詳細画面からでもお問い合わせいただけます。
| SCHEM No. | Structure | Compound Name | Price (JPY) | Purity | Stock(mg) |
|---|---|---|---|---|---|
| 02138 |  | Trt-PEG135-OBz(3,5-NO2) | 133,000/0.1mg | >80% | 0.1 |
| 04621 |  | OH-PEG27-O-BODIPY | 65,600/0.3mg | >90% | 0.1 |
| 04516 |  | DMT-PEG27-O-4-BODIPY | 64,600/0.5mg | >90% | 12.2 |
| 02139 |  | Trt-PEG27-Bz(3,5-NO2) | 64,600/0.5mg | >90% | 2.5 |
| 02140 |  | Trt-PEG18-Bz(3,5-NO2) | 64,600/0.5mg | >95% | 1.2 |
| 05950 |  | Sulforhodamine bis(CO-PEG14-COOH) | 68,800/0.1mg | >95% | 1.6 |
| 06798 |  | Cy5(1-PEG3-OMe 5-SO3H 8,8-diMe 1'-PEG13-COOH 8',8'-diMe) | 133,000/0.1mg | >95% | 0.1 |
| 06568 |  | (2-methyl-3-oxo-butoxy)-PEG13-COOH | 65,700/0.4mg | >95% | 0 |
| 06471 |  | TMI-PEG13-COOtBu | 133,000/0.1mg | >95% | 10.8 |
| 06461 |  | Cy5(PEG3-OMe)(PEG13-COOtBu) | 133,000/0.1mg | >95% | 0 |
| 06410 |  | Cy7(1-PEG13-COOH 5-SO3H 8,8-diMe 1'-PEG3-OMe 5'-SO3H 8',8'-diMe) | 133,000/0.1mg | >95% | 0.4 |
| 06401 |  | TMSI-PEG13-OTrt | 68,800/0.1mg | >95% | 0 |
| 06396 |  | AADIS7-PEG13-COOH | 133,000/0.1mg | >95% | 0.3 |
| 06390 |  | AADIS7-PEG13-COOtBu | 105,500/0.1mg | >95% | 0.9 |
| 06311 |  | TMSI-PEG13-COOH | 68,800/0.1mg | >95% | 11.1 |
| 06064 |  | Cy7(1-HexCONH-PEG13-COOtBu 5-SO3H 8,8-diMe 1'-Et-SO3H 8',8'-diMe) | 105,500/0.1mg | >95% | 0 |
| 05373 |  | Cy5(1-Pr-SO3H 5-SO3H 8-Me 8-Hex-CONH-PEG13-CONH-PEG2-Hex-Cl 1'-Pr-SO3H 5'-SO3H 8',8'-diMe) | 133,000/0.1mg | >90% | 0.1 |
| 05187 |  | BODIPY-4-O-PEG13-COOtBu | 68,800/0.1mg | >95% | 3.0 |
| 05078 |  | Cy5(1-Pr-SO3H 5-SO3H 8-Me 8-Hex-CONH-PEG13-COOtBu 1'-Pr-SO3H 5'-SO3H 8',8'-diMe) | 105,500/0.1mg | >90% | 0 |
| 04959 |  | BODIPY-4-O-PEG13-COOH | 105,500/0.1mg | >95% | 0.1 |
| 04746 |  | CF660R-PEG13-PEG2-O-HexCl | 133,000/0.1mg | >95% | 0.1 |
| 04731 |  | DY-547-CONH-PEG13-COOH | 69100/<0.1mg | >95% | 0.1 |
| 04730 |  | Texas-Red-X-CONH-PEG13-COOH mixed isomers | 69100/<0.1mg | >95% | 0.1 |
| 04729 |  | BODIPY FL C5-CONH-PEG13-COOH | 69100/<0.1mg | >95% | 0.1 |
| 04728 |  | 5(6)-TAMRA-CONH-PEG13-COOH | 69100/<0.1mg | >95% | 0.1 |
| 04727 |  | Cy3-CONH-PEG13-COOH | 68,800/0.1mg | >95% | 0.1 |
| 04726 |  | Cy5(1-Hex-CONH-PEG13-COOH 8,8-diMe 1'-Me 8',8'-diMe) | 69100/<0.1mg | >90% | 0.1 |
| 04722 |  | 5(6)-TAMRA-CONH-PEG13-COOtBu | 68,800/0.1mg | >95% | 0.1 |
| 04721 |  | Cy3-CONH-PEG13-COOtBu | 66,600/0.1mg | >95% | 0.1 |
| 04720 |  | Cy5(1-Hex-CONH-PEG13-COOtBu 8,8-diMe 1'-Me 8',8'-diMe) | 66,600/0.1mg | >90% | 1.5 |
| 04675 |  | PhNMe-PEG13-COOtBu | 64,600/0.5mg | >95% | 0.1 |
| 06560 |  | Trt-PEG12-EMOB | 66,700/0.7mg | >95% | 0 |
| 06479 |  | Cy5(1-PEG12-OMe 5-SO3H 8,8-diMe 1'-AcOtBu-8',8'-diMe | 68,800/0.1mg | >90% | 0.4 |
| 06456 |  | TMSI-PEG12-OMe | 68,800/0.1mg | >80% | 9.0 |
| 06394 |  | TMSI-PEG12-OH | 133,000/0.1mg | >95% | 6.1 |
| 06518 |  | Cy5(1-Hex-COOH 5-SO3H 8,8-diMe 1'-Et 5'-SO3H 8'-Me 8'-PEG11-OMe | 68,800/0.1mg | >90% | 0 |
| 06402 |  | Cy7(1-HexCOOH 5-SO3H 8,8-diMe 1'-PEG10-OAc 5'-SO3H 8',8'-diMe) | 68,800/0.1mg | >95% | 0 |
| 06069 |  | TMSI-PEG10-OH | 68,800/0.1mg | >95% | 0.1 |
| 06068 |  | TMSI-PEG10-OTrt | 63,400/0.2mg | >95% | 9.0 |
| 02137 |  | DMT-PEG9-Bz(3,5-NO2) | 70,800/2.5mg | >95% | 6.3 |
| 02136 |  | Trt-PEG9-Bz(3,5-NO2) | 64,000/0.7mg | >95% | 19.4 |
| 02134 |  | Trt-PEG9-NH-CSNH-FITC | 68,800/0.2mg | >95% | 1.8 |
| 06295 |  | TMSI-PEG8-OH | 64,000/0.7mg | >95% | 12.8 |
| 06398 |  | TMSI-PEG7-OH | 64,000/0.7mg | >95% | 1.3 |
| 06559 |  | Trt-PEG6-EMOB | 68,900/2.5mg | >95% | 0 |
| 06516 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG6-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >90% | 0 |
| 06432 |  | 1-(5-carboxypentyl)-2-[(E,3E)-3-[1-[2-(2-methoxyethoxy)ethyl]-3-methyl-5-sulfo-3-(3-sulfopropyl)indolin-2-ylidene]prop-1-enyl]-3-methyl-3-(3-sulfopropyl)indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06417 |  | Cy7(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG6-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06397 |  | TMSI-PEG6-OH | 64,000/0.7mg | >95% | 1.2 |
| 06796 |  | AADIS5-PEG5-COOH | 64,000/0.7mg | >95% | 0 |
| 06426 |  | Cy7(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG5-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06419 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG5-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >90% | 0 |
| 06294 |  | TMSI-PEG5-NHTrt | 68,800/0.1mg | >95% | 2.6 |
| 05978 |  | Fluorescein bis(NH2-PEG5) | 63,400/0.2mg | >95% | 1.1 |
| 04857 |  | Sulforhodamine bis(piperazine-PEG5-COOH) | 65,700/0.4mg | >95% | 7.0 |
| 04710 |  | Ph(Me)N-PEG5-COOtBu | 70,800/2.5mg | >95% | 2.9 |
| 07610 |  | TMI-PEG4-OTos | 66,300/25mg | >95% | 120.4 |
| 06895 |  | Cy5(1,1'-PEG4 8,8-diMe 8',8'-diMe) | 66,300/2.5mg | >95% | 2.2 |
| 06885 |  | TMI-PEG4-TMI | 64,900/7.5mg | >95% | 270.5 |
| 06858 |  | Trt-PEG4-EMOB | 66,300/2.5mg | >95% | 0 |
| 06511 |  | 3-(5-carboxypentyl)-1-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl]-2-[(1E,3E,5E)-5-[3-(2-methoxyethyl)-1-methyl-1-(3-sulfopropyl)benzo[e]indol-2-ylidene]penta-1,3-dienyl]-1-methyl-8-sulfo-benzo[e]indol-3-ium-6-sulfonate | 68,800/0.1mg | >90% | 0 |
| 06509 |  | 1-(5-carboxypentyl)-2-[(E,3Z)-3-[1-ethyl-3-[2-(2-methoxyethoxy)ethyl]-3-methyl-5-sulfo-indolin-2-ylidene]prop-1-enyl]-3-[2-(2-methoxyethoxy)ethyl]-3-methyl-indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06473 |  | DMSI(3-PEG4-COOH) | 64,000/0.7mg | >95% | 4.1 |
| 06434 |  | 2-[(E,3Z)-3-[1,3-bis[2-(2-methoxyethoxy)ethyl]-3-methyl-5-sulfo-indolin-2-ylidene]prop-1-enyl]-1-[2-[2-(2-carboxyethoxy)ethoxy]ethyl]-3-[2-(2-methoxyethoxy)ethyl]-3-methyl-indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06433 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-PEG4-OMe 1'-Et 5'-SO3H 8'-Me 8'-PEG3-OMe) | 68,800/0.1mg | >90% | 0 |
| 06422 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG4-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >90% | 0 |
| 06409 |  | Cy7(1-HexCOOH 5-SO3H 8,8-diMe 1'-PEG4-N3 8',8'-diMe) | 133,000/0.1mg | >95% | 0 |
| 06405 |  | AADIS7-PEG4-N3 | 68,800/0.1mg | >95% | 2.5 |
| 06293 |  | TMSI-PEG4-Pr-COOH | 64,000/0.7mg | >95% | 0 |
| 06062 |  | Cy7(1-PEG4-COOH 5-SO3H 8,8-diMe 1'-Me 5'-SO3H 8',8'-diMe) | 105,500/0.1mg | >95% | 0.1 |
| 06059 |  | AADIS7-PEG4-COOMe | 133,000/0.1mg | >95% | 3.9 |
| 06009 |  | Cy7(1-PEG4-COOMe 5-SO3H 8,8-diMe 1'-Me 5'-SO3H 8',8'-diMe) | 105,500/0.1mg | >95% | 0 |
| 05970 |  | Cy7(1-HexCOOH 5-SO3H 8,8-diMe 1'-PEG4-OH 8',8'-diMe) | 68,800/0.1mg | >95% | 0 |
| 05948 |  | TMSI-PEG4-OH | 68,800/0.2mg | >95% | 15.7 |
| 05075 |  | AADIS7-PEG3-OAc | 65,700/0.4mg | >95% | 3.0 |
| 04494 |  | OH-PEG4-O-4-BODIPY | 65,600/0.3mg | >95% | 0.9 |
| 04484 |  | BODIPY-4-O-PEG4-COOH | 64,600/0.5mg | >95% | 0.5 |
| 04483 |  | NH2-PEG4-O-2-BODIPY | 105,500/0.1mg | >95% | 0.1 |
| 03545 |  | TMSI-PEG4-COOMe | 68,800/0.1mg | >95% | 1.6 |
| 01592 |  | NH2-NH-PEG4-CONH-Fluorescein | 76,000/0.1mg | >90% | 0.1 |
| 01591 |  | Fluorescein PEG-NH(Boc)-NH2 | 133,000/0.1mg | >95% | 0.5 |
| 00207 |  | Cy3-CONH-PEG4-O-Et-CONHPrCOOH | 65,700/0.4mg | >95% | 44.6 |
| 06886 |  | TMI-PEG3-TMI | 64,900/7.5mg | >95% | 0 |
| 06884 |  | TMI-PEG3-OH | 64,900/7.5mg | >95% | 30.4 |
| 06556 |  | Trt-PEG3-EMOB | 66,300/2.5mg | >95% | 0 |
| 06512 |  | 3-(5-carboxypentyl)-1-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl]-2-[(1E,3E,5E)-5-[3-(2-methoxyethyl)-1-methyl-1-(3-sulfopropyl)benzo[e]indol-2-ylidene]penta-1,3-dienyl]-1-methyl-8-sulfo-benzo[e]indol-3-ium-6-sulfonate | 68,800/0.1mg | >90% | 0 |
| 06441 |  | 3',6'-bis[2-(2-aminoethoxy)ethylamino]spiro[isobenzofuran-3,9'-xanthene]-1-one | 65,700/0.4mg | >95% | 0 |
| 06431 |  | Cy7(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG3-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06430 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG4-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >90% | 0 |
| 06425 |  | Cy7(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG3-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06423 |  | Cy7(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG3-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06421 |  | 1-(5-carboxypentyl)-2-[(E,3E)-3-[1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-3-methyl-5-sulfo-3-(3-sulfopropyl)indolin-2-ylidene]prop-1-enyl]-3-methyl-3-(3-sulfopropyl)indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06420 |  | (3R)-1-(5-carboxypentyl)-2-[(E,3E)-3-[(3S)-1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-3-methyl-5-sulfo-3-(3-sulfopropyl)indolin-2-ylidene]prop-1-enyl]-3-methyl-3-(3-sulfopropyl)indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06393 |  | TMSI-PEG3-OMe | 64,000/0.7mg | >95% | 11.2 |
| 06061 |  | Cy7(1-Hex-COOH 5-SO3H 8,8-diMe 1'-PEG3-OAc 5'-SO3H 8',8'-diMe) | 105,500/0.1mg | >95% | 0.1 |
| 05976 |  | Fluorescein bis PEG3 | 68,800/0.1mg | >95% | 0.1 |
| 05445 |  | N-(4-bromoPEG3)-7-(diethylamino)-2-coumarine-3-carboxamide | 68,100/0.2mg | >80% | 28.0 |
| 05444 |  | N-(4-hydroxyPEG3)-7-(diethylamino)-2-coumarine-3-carboxamide | 64,600/0.5mg | >80% | 0.1 |
| 05146 |  | TMSI-PEG3-OH | 68,800/0.1mg | >95% | 89.4 |
| 05092 |  | Trt-PEG3-N(Me)-Ph | 64,600/0.5mg | >90% | 1.2 |
| 04477 |  | CC-PEG3-O-2-BODIPY | 64,600/0.5mg | >95% | 3.7 |
| 04475 |  | N3-PEG3-O-2-BODIPY | 64,600/0.5mg | >95% | 3.4 |
| 04236 |  | 5-(phenyl-PEG3-propyne)-10,15,20-triphenylporphyrin | 68,100/0.2mg | >80% | 5.3 |
| 04235 |  | 5-(phenyl-PEG3-methacryloyl)-10,15,20-triphenylporphyrin | 64,600/0.5mg | >80% | 3.2 |
| 04223 |  | 5-(phenyl-PEG3-N3)-10,15,20-triphenylporphyrin | 64,600/0.5mg | >80% | 9.4 |
| 01331 |  | Cy5(1-Hex-CONH-PEG3-NH2 5-SO3H 8,8-diMe 1'-Me 5'-SO3H 8',8'-diMe) | 64,000/0.7mg | >90% | 0 |
| 06887 |  | TMI-PEG2-TMI | 68,800/5mg | >95% | 0 |
| 06515 |  | 2-[(E,3E)-3-[3,3-dimethyl-5-sulfo-1-[2-[2-(4-sulfobutoxy)ethoxy]ethyl]indolin-2-ylidene]prop-1-enyl]-3,3-dimethyl-1-[2-[2-(4-sulfobutoxy)ethoxy]ethyl]indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06513 |  | 3-[2-[(1E,3E,5Z)-5-[3,3-dimethyl-5-sulfo-1-(3-sulfopropyl)indolin-2-ylidene]penta-1,3-dienyl]-3-[5-[2-(2-hydroxyethoxy)ethylamino]-5-oxo-pentyl]-3-methyl-5-sulfo-indol-1-ium-1-yl]propane-1-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06510 |  | Cy7(1-Pr-SO3H 5-SO3H 8-Me 8-Hex-CONH-PEG2-OMe 1'-Pr-SO3H 5'-SO3H 8',8'-diMe) | 68,800/0.1mg | >95% | 0 |
| 06440 |  | Cy7(1-HexCOOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG2-OMe 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06439 |  | Cy5(1-Hex-COOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG2-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >90% | 0 |
| 02819 |  | CR110-Halolinker | 68,800/0.1mg | >95% | 0.3 |
| 01979 |  | BODIPY halolinker | 105,500/0.1mg | >95% | 0.3 |
| 04622 |  | OH-PEG2K-O-BODIPY | 65,600/0.3mg | <80% | 0.5 |
| 06523 |  | Cy7(1-PEG4-COOH 5-SO3H 8,8-di-Me 1'-PEG4-COOH 5'-SO3H 8',8'-diMe)(4-Et-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06522 |  | Cy7(1-HexCOOH 5-SO3H 8-Me 8-Pr-SO3H 1'-PEG4-OMe 5'-SO3H 8'-Me 8'-Pr-SO3H) | 68,800/0.1mg | >95% | 0 |
| 06521 |  | 1-(5-carboxypentyl)-2-[(E,3E)-3-[1-[2-(2-methoxyethoxy)ethyl]-3-methyl-5-sulfo-3-(3-sulfopropyl)indolin-2-ylidene]prop-1-enyl]-3-methyl-3-(3-sulfopropyl)indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06520 |  | Cy5(1-PEG4-Pr-COOH 5-SO3H 8-Me 8-PEG4-OMe 1'-PE4-OMe 5'-SO3H 8'-Me 8'-PEG4-OMe) | 68,800/0.1mg | >90% | 0 |
| 06519 |  | Cy7(1-HexCOOH 5-SO3H 8-Me 8-PEG4-OMe 1'-Et 5'-SO3H 8'-Me 8'-PEG4-OMe) | 68,800/0.1mg | >95% | 0 |
| 06514 |  | 1-ethyl-2-[(E,3E)-3-[1-[6-(2-hydroxyethoxy)-6-oxo-hexyl]-3,3-dimethyl-5-sulfo-indolin-2-ylidene]prop-1-enyl]-3,3-dimethyl-indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 06446 |  | 3-[2-[2-[(2E)-2-[(E)-3-[3,3-dimethyl-1-[2-[2-(3-sulfopropoxy)ethoxy]ethyl]indol-1-ium-2-yl]prop-2-enylidene]-3,3-dimethyl-indolin-1-yl]ethoxy]ethoxy]propane-1-sulfonic acid | 68,800/0.1mg | >95% | 0 |
| 06424 |  | 2-[[6'-[2-(2-aminoethoxy)ethylamino]-3-oxo-spiro[isobenzofuran-1,9'-xanthene]-3'-yl]amino]acetic acid | 68,800/0.1mg | >95% | 0 |
| 06418 |  | Cy7(1-PEG5-COOH 5-SO3H 8-Me 8-PEG4-OMe 1'-PEG4-OMe 5'-SO3H 8'-Me 8'-PEG4-OMe) | 68,800/0.1mg | >95% | 0 |
| 06416 |  | 1-(5-carboxypentyl)-2-[(E,3E)-3-[1-[2-(2-methoxyethoxy)ethyl]-3-methyl-5-sulfo-3-(3-sulfopropyl)indolin-2-ylidene]prop-1-enyl]-3-methyl-3-(3-sulfopropyl)indol-1-ium-5-sulfonate | 68,800/0.1mg | >95% | 0 |
| 01980 |  | Cy3-halolinker | 63,400/0.2mg | >95% | 0.1 |
